CD19 CAR-T细胞治疗慢性淋巴细胞白血病应答与耐药的决定因素
该研究通过对慢性淋巴细胞白血病(CLL)患者来源的CAR-T细胞进行基因组、表型和功能评估,发现完全应答者的CAR-T细胞富集记忆相关基因(含IL-6/STAT3信号),而无应答者上调效应分化、糖酵解、耗竭和凋亡程序。治疗前CD27+CD45RO-CD8+T细胞频率升高与持续缓解相关,且CD27+PD-1-CD8+ CAR-T细胞高表达IL-6受体可预测治疗应答并负责肿瘤控制。
要点
- 治疗前CD27+CD45RO-CD8+T细胞频率高与CAR-T治疗后持续缓解相关。
- 完全应答者CAR-T细胞富集记忆相关基因和IL-6/STAT3特征,无应答者上调耗竭与凋亡程序。
- CD27+PD-1-CD8+ CAR-T细胞高表达IL-6受体,可预测应答并介导肿瘤控制。
核心结论
- CAR-T细胞记忆相关特征和IL-6/STAT3信号与CLL患者治疗应答相关,而效应分化、耗竭和凋亡程序与无应答相关。
- 治疗前CD27+CD45RO-CD8+T细胞频率及CD27+PD-1-CD8+ CAR-T细胞亚群可预测治疗应答。
研究设计与样本
- 对接受CD19 CAR-T细胞治疗的CLL患者来源的CAR-T细胞进行基因组、表型和功能评估。
主要发现
- 完全应答者CAR-T细胞富集记忆相关基因,包括IL-6/STAT3特征;无应答者上调效应分化、糖酵解、耗竭和凋亡程序。
- 持续缓解与治疗前CD27+CD45RO-CD8+T细胞频率升高相关,这些淋巴细胞具有记忆样特征。
- 患者功能性CAR-T细胞产生STAT3相关细胞因子,血清IL-6与CAR-T细胞扩增相关。
- IL-6/STAT3阻断减弱CAR-T细胞增殖。
- CD27+PD-1-CD8+ CAR-T细胞高表达IL-6受体,预测治疗应答并负责肿瘤控制。
临床怎么用
- 治疗前检测CD27+CD45RO-CD8+T细胞频率和CD27+PD-1-CD8+ CAR-T细胞亚群可能有助于预测CLL患者对CD19 CAR-T治疗的应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tolerance to self-antigens prevents the elimination of cancer by the immune system1,2. We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with chronic lymphocytic leukemia (CLL). Remission was induced in a subset of subjects, but most did not respond. Comprehensive assessment of patient-derived CAR T cells to identify mechanisms of therapeutic success and failure has not been explored. We performed genomic, phenotypic and functional evaluations to identify determinants of response. Transcriptomic profiling revealed that CAR T cells from complete-responding patients with CLL were enriched in memory-related genes, including IL-6/STAT3 signatures, whereas T cells from nonresponders upregulated programs involved in effector differentiation, glycolysis, exhaustion and apoptosis. Sustained remission was associated with an elevated frequency of CD27+CD45RO-CD8+ T cells before CAR T cell generation, and these lymphocytes possessed memory-like characteristics. Highly functional CAR T cells from patients produced STAT3-related cytokines, and serum IL-6 correlated with CAR T cell expansion. IL-6/STAT3 blockade diminished CAR T cell proliferation. Furthermore, a mechanistically relevant population of CD27+PD-1-CD8+ CAR T cells expressing high levels of the IL-6 receptor predicts therapeutic response and is responsible for tumor control. These findings uncover new features of CAR T cell biology and underscore the potential of using pretreatment biomarkers of response to advance immunotherapies.
引用
- Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018. PMID: 29713085. doi:10.1038/s41591-018-0010-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。